The future of depression treatment is data-driven

Setting the standard for precision psychiatry​

Changing the way depression is treated


We’re shaping the future of precision psychiatry by using objective measures to diagnose and treat depression. We use clinically reliable indicators of brain function to develop objective, brain-based patient categories - otherwise known as neurotypes. At Universal Brain we're translating cutting-edge knowledge from clinical neuroscience research to identify subtypes of depression.

Our Solutions


For Biopharma & HCPs

We’ve developed the first and only neuroscience-based platform to biotype and treat psychiatric conditions using brain function, and we’re starting with depression. Using a next generation EEG wearable paired with our digital ERP interface, NeurotiqueTM, we provide users with interpretable data about their cognitive and emotional abilities, aiding with diagnosis and treatment decisions. This can be applied to psychiatric clinical drug trials and to aid clinicians in diagnosis and treatment decision making.

For Patient Treatment

We’ve also developed a gamified neurofeedback treatment system (EEG wearable + digital therapeutic) that modulates the brain activity associated with depressive symptoms. Patients will engage in a dynamic, 4-week training session designed to monitor brain activity and provide real-time feedback to alleviate depressive symptoms. This can augment clinician treatment with patients.

What is Neurotyping?


Neurotyping is grouping people based on functional brain measures derived from EEG data collected while completing a series of tasks. Neurotyping involves measuring cognitive and emotional abilities, using reliable and valid neuroscience measures of brain function. It can reduce heterogeneity, enable patient selectivity, increase clinical trial outcomes, and help clinicians better understand their patient’s diagnoses to improve treatment. Universal Brain’s platform provides insights about functional neural measures so that each person can be understood in terms of their own unique profile of brain function.

How it works


Psychiatric disorders, like depression, are complex and a one-size-fits-all approach is a barrier to improving outcomes. Rather than focusing solely on expressed/endorsed symptoms, we create patient classifications based on underlying neural function. By neurotyping patients, we examine the functioning of core neural systems – everything from attention to memory. We derive subtypes of depression based on patterns of associations between these functional neural measures.

Universal Brain Platform

Next generation
EEG Headset

+

NeurotiqueTM ERP APP

+

Algorithm Driven Software

=

Targeted Treatment
for 
Improved outcomes

We’re on a mission to make data-driven decisions and shift the paradigm of how we understand and treat depression and psychiatric disorders.

Meet the Team


Management Team

Kazu Okuda, M.D.
Founder & CEO

K.T. Venkateswara-Rao, PhD
Head of Operations

Greg Hajcak, PhD
Chief Scientific Advisor​

Vangelis Lympouridis, PhD
Chief Product Officer

Kirsten Carlson
Head of Commercialization

Advisory Team

Shigenobu Kanba, MD, PhD
Scientific Advisor

Yoshiya Moriguchi, MD, PhD
Collaborator

Naoya Oribe, MD, PhD
Collaborator

Josh Sackman
Executive Advisor

Kern Bhugra
Executive Advisor

Let’s work together.


News

NEWS

Universal Brain Expands
Executive Team to Accelerate
Precision Psychiatry